Clene (CLNN) New CNM-Au8 Data "Restore Opportunity" - Oppenheimer Raises PT to $17 Aug 16, 2022 04:39PM
Clene, Inc. (CLNN) PT Lowered to $16 at Oppenheimer, "Outperform" Rating Maintained, New CNM-Au8 Data "Support Candidate's Potential" Jun 2, 2022 07:23AM
Oppenheimer Reiterates Outperform Rating on Clene (CLNN), Sees ALS Readout as Coming Next Quarter Apr 5, 2022 06:32AM
Clene, Inc. (CLNN) PT Lowered to $19 at Oppenheimer, but Reiterated Optimism for CNM-Au8's Top-line Phase 2/3 results in ALS Feb 15, 2022 06:14AM